UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________ FORM 10-K _________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 1-5353 ____________________________ ...

Financial Data and Key Metrics Changes - In Q4 2021, Teleflex achieved 7.9% constant currency revenue growth year-over-year and 10.4% growth compared to Q4 2019, with an adjusted earnings per share increase of 10.8% year-over-year [10][14][43] - For the full year 2021, constant currency sales growth was 8.8%, adjusted operating margin expanded by 310 basis points, and adjusted earnings per share reached $13.33, a 24.9% increase year-over-year [14][43] Business Line Data and Key Metrics Changes - Americas revenue was $451.7 million in Q4, representing 7.6% year-over-year growth, driven by Surgical, Vascular, and Interventional segments [17] - EMEA revenues increased 4.8% year-over-year to $164.5 million, with Interventional, Surgical, and Vascular Access products leading the growth [17] - Asia revenues were $78.5 million, a 0.5% year-over-year increase, with a 6.7% rise when excluding the respiratory divestiture [18] - Vascular Access revenue grew 6.4% to $193 million, with notable growth in the PICC portfolio [19] - Interventional revenue was $114.9 million, up 8.2% year-over-year, with strong demand for complex catheters [20] - Anesthesia and Emergency Medicine revenue increased 20.5% to $102.8 million, driven by Hemostat products [22] - Surgical revenue was $106.4 million, representing 16.1% growth year-over-year [22] - Interventional Urology revenue decreased 1% year-over-year to $92.9 million, impacted by COVID-19 [23] - OEM revenues increased 3.9% year-over-year to $67.2 million [23] - Other category revenues declined 12.2% to $84.7 million due to the respiratory divestiture [24] Market Data and Key Metrics Changes - The Americas, EMEA, Asia, and OEM segments all demonstrated constant currency revenue growth over 2020, despite COVID-19 headwinds [16] - The company noted that COVID-19 significantly impacted elective surgical procedures, particularly in December [12][13] Company Strategy and Development Direction - Teleflex is focused on driving durable growth, expanding margins, and optimizing its portfolio through acquisitions and divestitures [14][40] - The company plans to enhance its UroLift product line and expand into international markets, with significant opportunities in Japan and Brazil [30][32] - The strategy includes maintaining financial discipline while pursuing M&A opportunities in the $60 million to $300 million revenue range [68][76] Management's Comments on Operating Environment and Future Outlook - Management expects the impact of COVID-19 to be lower in 2022 compared to 2021, with improvements in elective surgical procedures anticipated [37][38] - The company is prepared to adjust spending based on the level of COVID disruption while continuing to invest in growth drivers [39] - For 2022, constant currency revenue growth is expected to be between 4% and 5.5%, with UroLift projected to grow approximately 15% [48][49] Other Important Information - Adjusted gross margin for Q4 was 58.8%, an 80 basis point increase year-over-year, while adjusted operating margin was 27.6%, a 100 basis point increase [42] - Cash flow from operations for 2021 totaled $652.1 million, a significant increase from $437.1 million in 2020 [44] - The company has a solid balance sheet with a cash balance of $445.1 million and net leverage of approximately 1.7x [45] Q&A Session Summary Question: Current environment compared to a month ago - Management noted that parts of the business perform differently during COVID outbreaks, with expectations for improvement in February and March as hospitals reopen [64][66] Question: Portfolio optimization in the current environment - Management expressed confidence in their financial position and ability to pursue acquisitions, noting improved valuation expectations [68][69] Question: UroLift growth and reimbursement changes - UroLift is expected to grow 15% in 2022, with contributions primarily from the U.S. market, while international markets will ramp up in subsequent years [71][73] Question: M&A criteria and areas of interest - The company is looking for assets in the $60 million to $300 million revenue range that fit strategic pillars and have strong IP [76] Question: UroLift growth cadence and international contributions - UroLift growth is expected to be lower in the first half of 2022 due to COVID, with stronger growth anticipated in the second half [81] Question: Impact of inflation and FX on margins - Inflation in Q4 was higher than expected, and management anticipates continued inflationary pressures in 2022, impacting margins [88][90]

| --- | --- | --- | |--------------------------------------------------------------------|-------|-------| | | | | | | | | | | | | | Teleflex Incorporated Fourth Quarter 2021 Earnings Conference Call | | | ിfeleflex® Conference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) An audio replay of the call will be available beginning at 11:00 am Eastern Time on February 24, 2022 either on the Teleflex website or by telephone. The ...

Financial Data and Key Metrics Changes - Teleflex generated third quarter revenue of $700.3 million, an increase of 10.3% year-over-year on a constant currency basis, reflecting the benefits of a diversified portfolio [17] - Adjusted earnings per share (EPS) for the third quarter was $3.51, representing a 26.7% increase year-over-year, exceeding internal expectations [19][53] - The company reduced its constant currency revenue growth outlook for the year to a range of 8% to 9% from a previous range of 8.5% to 9.75% [16][57] Business Line Data and Key Metrics Changes - Americas revenues were $417.3 million, up 10.9% year-over-year, driven by Surgical, Vascular, and Interventional products [22] - EMEA revenues increased 3.6% year-over-year to $143.9 million, with growth led by Interventional and Vascular products [23] - Asia revenues grew 6.3% year-over-year to $75 million, with Japan showing strong growth of over 30% [24] Market Data and Key Metrics Changes - All regions (Americas, EMEA, Asia, and OEM) demonstrated constant currency revenue growth over 2020, despite headwinds from the Delta variant [14] - The OEM business accounted for approximately 9% of total sales, increasing 29.4% year-over-year to $64.1 million [34] Company Strategy and Development Direction - The company continues to execute its strategy focused on durable growth through investments in organic growth opportunities, product innovation, and margin expansion [20][65] - Teleflex is committed to maintaining its leadership position in the UroLift market, targeting patients suffering from BPH [32][81] Management Comments on Operating Environment and Future Outlook - Management acknowledged ongoing uncertainty around COVID-19 infections and the impact on elective surgical procedures, expecting a more normalized environment in 2022 [15][66] - The company anticipates modest improvement in the fourth quarter compared to the third quarter, but remains cautious about the macro environment [15][16] Other Important Information - The adjusted gross margin for the third quarter was 59.5%, a 230 basis point increase year-over-year, driven by product mix and cost improvement initiatives [52] - The company is experiencing increased cost pressures in raw materials and logistics, with an estimated $3 million higher inflationary costs expected in the fourth quarter [60][61] Q&A Session Summary Question: What are the assumptions for Q4 and recent trends? - Management indicated that Q4 assumptions are based on stability, with some subdued trends observed in late Q3, and noted improvements in procedure volumes in September [70] Question: How is the company preparing for different reimbursement scenarios? - Management emphasized the importance of engaging with CMS regarding the proposed ruling and expressed confidence in the UroLift procedure's profitability across various care settings [73][76] Question: What impact have staffing shortages had on operations? - Management noted that staffing shortages are expected to improve as government assistance ends, leading to a return of ancillary workers to the workforce [85][91] Question: How substantial is the impact of nursing shortages? - Management acknowledged that nursing shortages are significant, particularly in hospitals, and may take longer to resolve compared to office settings [90][92] Question: What is the outlook for UroLift amidst reimbursement uncertainties? - Management expressed confidence that the headwinds faced in Q3 were primarily due to COVID-19 and not related to reimbursement issues, anticipating a recovery in procedures [95][99]

Teleflex Incorporated (NYSE:TFX) Q2 2021 Results Earnings Conference Call July 29, 2021 8:00 AM ET Company Participants Lawrence Keusch - Vice President, Investor Relations and Strategy Development Liam Kelly - Chairman, President and Chief Executive Officer Thomas Powell - Executive Vice President and Chief Financial Officer Conference Call Participants Matthew Taylor - UBS Securities LLC Cecilia Furlong - Morgan Stanley Shagun Singh-Chadha - Wells Fargo Securities Matthew O'Brien - Piper Sandler Companies ...

| --- | --- | |--------------------------|-------| | | | | Teleflex Incorporated | | | Second Quarter 2021 | | | Earnings Conference Call | | 1 ിfeleflex® Conference Call Logistics (investors link) 2 The release, accompanying slides, and replay webcast are available online at www.teleflex.com An audio replay of the call will be available beginning at 11:00 am Eastern Time on July 29, 2021 either on the Teleflex website or by telephone. The call can be accessed by dialing (800) 585-8367 (U.S./ Canada) or (41 ...

1 Teleflex Investor Presentation ിfeleflex® Forward Looking Statements 2 This presentation and our discussion contain forward-looking information and statements, which inherently involve risks and uncertainties that could cause actual results to differ from those projected or implied in the forward–looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking st ...

Financial Data and Key Metrics Changes - In Q1 2021, revenue was $633.9 million, down 2.6% year-over-year on a constant currency basis, primarily due to COVID-19 impacts [6][9] - Adjusted earnings per share (EPS) was $2.87, up 5.5% year-over-year, exceeding expectations [8][25] - Adjusted gross margin was 59.4%, an increase of 210 basis points year-over-year, while adjusted operating margin was 27.5%, up 190 basis points [9][23] Business Line Data and Key Metrics Changes - Vascular Access revenue increased by 5.8% to $164 million, with a 9.3% increase adjusted for selling days [13] - Interventional Access revenue decreased by 6.4% to $96.2 million, with a 3.8% decline adjusted for selling days [14] - Anesthesia revenue grew by 7% to $84.9 million, or 9.9% adjusted for selling days [15] - Surgical revenue was $80.4 million, representing 2.3% growth or 4.7% adjusted for selling days [16] - Interventional Urology revenue declined by 1.3% to $73.4 million, with a 1.9% increase adjusted for selling days [17] - Other category revenue declined by 15.3% to $81.7 million, or 12.6% adjusted for selling days [18] Market Data and Key Metrics Changes - Americas revenue was $375.5 million, up 4.7% or 8.3% on a day sales adjusted basis [11] - EMEA revenue was $141.2 million, down 16.9% or 14.4% on a day sales adjusted basis [11] - Asia revenue totaled $63.7 million, representing 10.3% growth with no selling day impact [12] Company Strategy and Development Direction - The company is focused on continuous improvement and efficiency through a new restructuring plan aimed at streamlining business functions [8][25] - The integration of the HPC acquisition has been completed, with additional capacity expected to drive growth in the second half of the year [13] - The company anticipates significant growth in the Interventional Urology segment, expecting at least 30% growth over 2020 levels [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the recovery of procedures as COVID-19 impacts lessen, particularly in the UroLift segment [41][49] - The company raised its revenue growth guidance for 2021 to between 8.5% and 9.75% on a constant currency basis, reflecting strong Q1 performance [28][31] - Management noted that the Americas and Asia are recovering more quickly than Europe [12] Other Important Information - The company expects to realize total annual pretax savings of between $13 million and $16 million from the restructuring plan once fully implemented [25][26] - Cash flow from operations totaled $110.8 million, a significant increase from a net use of cash in the prior year period [27] Q&A Session Summary Question: Trends on UroLift and growth expectations - Management indicated that UroLift growth in Q1 2021 was approximately 30% compared to Q1 2019, with expectations for continued growth [38][40] Question: Management changes and market perception - Management confirmed that while there were changes in leadership, the core team remains stable, and the culture at Teleflex supports retention [41] Question: UroLift expansion and DTC campaign - Management plans to run a national DTC campaign for the full year, expecting significant patient engagement and procedure recovery as confidence returns [48][49] Question: Competitive landscape for UroLift - Management reported no significant changes in the competitive landscape and emphasized strong patient outcomes as a key differentiator [76] Question: EMEA market recovery - Management noted that EMEA is lagging but expects a reversal as COVID restrictions ease [80]

1 | --- | --- | --- | --- | |-----------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | Teleflex Incorporated | | | | | Q1 2021 Earnings Conference Call | | | | Conference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on "Investors") Telephone replay is available by dialing (800) 585-8367 or for international calls, (416) 621-4642, conference ID 6194708 2 Today's Speakers Liam Kelly Chairman, President an ...

1 Teleflex Investor Presentation ിfeleflex® Forward Looking Statements 2 This presentation and our discussion contain forward-looking information and statements, which inherently involve risks and uncertainties that could cause actual results to differ from those projected or implied in the forward–looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking st ...